Horizon Therapeutics Receives $7,294,000 New Financing

  • Feed Type
  • Date
    3/31/2010
  • Company Name
    Horizon Therapeutics
  • Mailing Address
    1033 Skokie Boulevard Northbrook, IL 60062
  • Company Description
    Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, will enter Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combination products in earlier stages of development.
  • Website
    http://www.horizontherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $7,294,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Essex Woodlands Health Ventures
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.